Sigma Planning Corp Cuts Stock Position in Tempus AI, Inc. $TEM

Sigma Planning Corp trimmed its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 82.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,129 shares of the company’s stock after selling 19,302 shares during the quarter. Sigma Planning Corp’s holdings in Tempus AI were worth $244,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. GC Wealth Management RIA LLC purchased a new stake in Tempus AI in the 4th quarter worth $399,267,000. Vanguard Group Inc. lifted its holdings in Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Voloridge Investment Management LLC grew its position in shares of Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after purchasing an additional 1,039,176 shares during the period. BNP Paribas Financial Markets grew its position in shares of Tempus AI by 312.7% in the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after purchasing an additional 965,730 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in shares of Tempus AI during the second quarter worth about $54,020,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $49.86 on Friday. The firm has a 50-day simple moving average of $50.32 and a 200-day simple moving average of $62.37. The company has a quick ratio of 3.00, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The stock has a market capitalization of $8.91 billion, a price-to-earnings ratio of -28.99 and a beta of 3.99. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period in the previous year, the business posted ($0.24) earnings per share. Tempus AI’s quarterly revenue was up 36.1% on a year-over-year basis. On average, equities analysts predict that Tempus AI, Inc. will post -1.39 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Erik Phelps sold 9,464 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total transaction of $562,445.52. Following the transaction, the executive vice president directly owned 79,816 shares in the company, valued at $4,743,464.88. The trade was a 10.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Andrew Polovin sold 10,949 shares of Tempus AI stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the transaction, the executive vice president owned 126,918 shares in the company, valued at approximately $7,654,424.58. The trade was a 7.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 563,471 shares of company stock worth $29,837,342. 24.26% of the stock is currently owned by insiders.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG Research lowered its price target on Tempus AI but kept a Buy rating, signaling continued confidence in the stock’s long-term upside despite near-term valuation pressure. BTIG lowers Tempus AI price target but keeps Buy rating
• Positive Sentiment: Several recent writeups highlighted Tempus AI’s growing role in precision medicine, its AI-powered diagnostics platform, and its data licensing partnerships with biopharma, which support the bull case for long-term revenue growth and margin expansion. Seeking Alpha article on Tempus AI precision medicine demand
• Positive Sentiment: Coverage also pointed to Tempus AI’s earnings-call theme of improving growth and profitability, reinforcing expectations that recent operating momentum may continue. Tempus AI earnings call highlights growth and profitability
• Neutral Sentiment: Tempus AI announced a $400 million upsized offering of 0.00% convertible senior notes due 2032 and separately outlined a proposed $350 million convertible note sale, moves that may help reduce interest expense and optimize capital structure, but could also add dilution concerns. Tempus announces pricing of upsized convertible senior notes offering
• Neutral Sentiment: Additional headlines about expanding convertible note offerings and broader AI stock interest from Cathie Wood are drawing attention, but these items are more about market sentiment than a direct fundamental catalyst for TEM. Tempus AI and Scorpio Tankers expand convertible note offerings

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TEM shares. Guggenheim reduced their price target on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Robert W. Baird assumed coverage on Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock. TD Cowen boosted their price objective on Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research report on Wednesday, March 11th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and a consensus price target of $70.86.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.